Company Filing History:
Years Active: 2009-2012
Title: The Innovative Contributions of Sabine Eming
Introduction
Sabine Eming is a prominent inventor based in Cologne, Germany. She has made significant contributions to the field of biotechnology, particularly in the development of vascular endothelial growth factor (VEGF) mutants. With a total of two patents to her name, her work focuses on advancing medical treatments for chronic wounds.
Latest Patents
Eming's latest patents include innovative approaches to proteolysis resistant active VEGF. The first patent details the modification of VEGF by replacing the alanine at amino acid position 111 with proline. Additionally, the arginine at amino acid position 110 can be substituted with another amino acid. This invention also encompasses derivatives of the modified VEGF, nucleic acids, expression systems, and medicaments aimed at treating chronic wounds. The second patent reiterates these modifications and their applications in medical treatments, emphasizing the importance of her research in improving patient outcomes.
Career Highlights
Sabine Eming is associated with Bayer Innovation GmbH, where she continues to push the boundaries of scientific research. Her work has garnered attention for its potential to revolutionize treatments for chronic wounds, showcasing her dedication to innovation in the medical field.
Collaborations
Eming collaborates with notable colleagues such as Thomas Krieg and Stephan Sollberg, contributing to a dynamic research environment that fosters innovation and development.
Conclusion
Sabine Eming's contributions to the field of biotechnology through her patents on VEGF mutants highlight her role as a leading inventor. Her work not only advances scientific knowledge but also has the potential to significantly impact medical treatments for chronic wounds.